The Efficacy of Selumetinib in Chinese Paediatric Participants With Post-operative Neurofibromatosis Type 1 (NF1)-Associated PNs: A PhaseⅡ, Multicenter, Randomised, Double-Blinded, Placebo-Controlled Study
Latest Information Update: 17 Aug 2023
At a glance
- Drugs Selumetinib (Primary)
- Indications Neurofibromatosis 1
- Focus Therapeutic Use
- Acronyms PROTECT
- Sponsors AstraZeneca
Most Recent Events
- 10 Aug 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 26 Apr 2023 New trial record